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1. Introduction
Traumatic brain injury (TBI) is an event that occurs suddenly and has long lasting effects
to the brain that are dependent on the severity of insult. Symptoms can range from mild
to severe. It is a well-established notion that imbalances in the production of reactive oxygen
species (ROS),  reactive nitrogen species (RNS),  and native antioxidant mechanisms have
been shown to increase oxidative stress. Multiple research efforts have evaluated the use
of pre-injury therapies on moderate TBI; however since traumatic brain injuries are sudden,
treatment should begin post-injury. There is no known cure for TBI, although flavonoids,
neurosteroids, statins, gamma-glutamylcysteine ethyl ester, and novel histone deacteylase
inhibitors show therapeutic promise. Hence, therapeutic strategies that improve outcomes
following  injury  and  the  time  at  which  treatment  is  most  beneficial  is  paramount.  As
traumatic brain injury has been shown to alter energy metabolism and the use of redox
proteomics and enzyme kinetics has been used to investigate the oxidative modification of
proteins that  may lead to reduced cognition observed in TBI patients.  This  chapter  will
evaluate  the  current  therapeutic  modalities  for  traumatic  brain  injury in  various  animal
models as well as affected patients. It will also discuss the role of redox proteomics and
enzyme kinetics in traumatic brain injury, most importantly how these oxidatively modified
proteins play a role in learning and memory, both of which are effected in those affected
by traumatic brain injury.
© 2014 Sellers et al.; licensee InTech. This is a paper distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Current models
The field of traumatic brain injury research employs multiple animal models to investigate
consequences of this devastating injury. Glutathione (GSH) is the major antioxidant in the
brain, therefore treatment of neurodegenerative diseases including traumatic brain injury
(TBI) with GSH is of great interest. Alzheimer’s disease and other classically diagnosed
neurodegenerative diseases have similar patterns of decreased GSH as found in blast induced
TBI by fluorescence assay [1]. Proposed studies utilizing rat models incorporate prevention of
secondary insults post-TBI with a glutathione mimetic. Omega-3 fatty acids from fish oils as
a dietary supplement are used in multiple mild TBI rat models as a preventative measure [2].
This study was found to show cognitive improvement and weight loss recovery post-injury
when a 6% fish oil supplement containing omega-3 fatty acids was given as a regular dietary
supplement prior to the injury [2]. Axonal damage can cause detrimental effects on the brain.
Axonal damage due to TBI results in loss of elasticity in axons making them brittle, swollen,
and dramatically stretched allowing calcium to enter the axons leading to extensive damage
by initiating a protease cascade [3]. In order to determine the efficiency and safety of future
human TBI treatment for restoration of axonal damage, recently rat models have been used as
a preliminary study for stem cell treatment for TBI [4]. While understanding axonal damage
is important when researching TBI, metabolic rat model studies are exploring cerebral glucose
uptake in TBI metabolic pathways [5]. Results show that a decrease in cerebral glucose uptake
occurs in TBI rat models with axonal damage and glial activation [5]. Therefore, glucose is
unable to be transported out of the cell for use as fuel to the body, much like insulin resistance
in Type-2 diabetes. Additionally, rat models are utilized to determine histone deacetylase
inhibitors (HDACi) in post injury treatment as a neuroprotectant in acute TBI [6]. HDAC
inhibitors activate neurotrophic tyrosine kinase receptor type 1 (TrKA) and nerve growth
factor (NGF) expression present significant results in preventing cell apoptosis [6]. Conse‐
quently, HDAC inhibitors are able to prevent cell death post-TBI. Findings support a decrease
of glial fibrillary acidic protein (GFAP), a biomarker for neurotoxicity in damaged tissues [6,
7]. As findings in rat studies are gaining positive results, progressive animal models with
physiology closer to humans are being incorporated into TBI research.
TBI is a growing issue among military personnel, athletes, and victims of all ages and back‐
grounds; therefore, it is of great importance to include a variety of animal models with
physiological properties close to humans. Use of a neonatal piglet TBI model has increased
due to their similarities in human myelin sheath, tissue morphology, cerebral structure, and
development [8]. Neonatal piglet TBI research allows for future research in behavioral and
cognitive assessment and is presumed to be utilized as a tool for preventing secondary injury,
such as stroke and resuscitation strategies [9]. Canine epilepsy due to traumatic brain injury
has brought insight into therapeutic strategies for posttraumatic epilepsy (PTE) as secondary
insult of human TBI [10]. Researchers hope to find treatments in the canine model that will
greatly benefit clinical research of TBI as epilepsy and seizures are a severe secondary insult
that can lead to detrimental cognitive issues, specifically due to the seizures increasing weeks
after the initial injury [10, 11]. Hypothermia treatment has been considered for post-TBI
therapy, although clinical trials have not been completed at this time [12]. Previous research
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demonstrated that rat and swine models have shown positive results with hypothermia
experiments as preventative measures against neurodegeneration and currently non-human
primates are the prime model for this study [12-14]. A product known as the “chiller-pad” has
been used in trials to determine its effectiveness on neuroprotection. Results are encouraging,
although the need for a craniotomy to allow hypothermia to be addressed at an exact locality
is a perceived downside [12, 13]. It is unclear how hypothermia protects neurodegeneration;
however it is necessary to localize cooling, as to not reduce overall body temperature [12].
Rhesus monkey models ranging from ages 3.9 to 14 years old have been used in a long-term
study to determine the effects of microglia as defense against injured neurons in the brain and
spinal cord after TBI [15]. Most studies appear to monitor the crucial timeframe of TBI, which
typically falls immediately after the injury’s occurrence [15, 16]. This study allows scientists to
view the effects of progression or degression of each monkey for one year [15, 17]. The results
encourage further study into therapy with genetic manipulation of microglial phenotype to
determine the functionality of impairment on the recovery process as well as anti-inflamma‐
tory treatment [15, 17].
Overall, the previous and current studies for traumatic brain injury have been beneficially
positive for future studies and treatment for TBI. Researchers are aware that there is still an
informational gap in understanding the mechanisms behind TBI and therapeutic strategies,
but with future studies and the scientific, as well as public communities’ increasing awareness,
there will be a bridge to close that gap of uncertainty [18].
3. Pre and post injury strategies
Pre-injury traumatic brain injury (TBI) strategies occur prior to the injury as preventative
measures, while post-injury TBI strategies are therapeutic measures taken to prevent secon‐
dary insult from occurring after the injury, as there is no way to reverse the initial injury, but
further damage can be prevented. With the increasing awareness of TBI, research for preven‐
tative and post injury measures is on the rise. There are numerous studies with a variety of
computational and animal models that depict a range of TBI severities. There are definite
correlations between past and present studies as well as connections between different animal
models, with a hopeful finality for positive treatment of humans with TBI.
Researchers are developing statistical models to compare different TBI patient populations in
order to determine which new therapies would be most beneficial. The Traumatic Brain Injury
National Data and Statistical Center has developed a longitudinal prospective cohort study
utilizing Extended Glasgow Outcome scale (GOS-E) scores to determine the furtherance of
secondary insult over a period time after the TBI has occurred [19]. The parameters for this
model include initial (GOS-E) scores, Functional measure of independence (FIMTM), race,
gender, and reusable learning objects (RLOS) [19, 20]. In addition to statistical data, many of
the testing strategies require the use of psychological testing to determine pre and post coping
models of TBI in humans. The testing mechanism for these models include Coping Scale for
Adults (Short Version), Quality of Life Inventory, Sydney Psychosocial Reintegration Scale,
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and Hospital Anxiety and Depression Scale during 36 months post-injury [21]. In 2008, the
Department of Veterans Affairs Polytrauma System of Care partnered with the Department
of Education to perform ongoing research with longitudinal patterns using the Traumatic
Brain Injury Model Systems of Care (TBIMS) project in order to keep track of rehabilitating
veterans with TBI [22].
Where some studies investigate computational approaches to evaluating traumatic brain
injury progression in patients, others are utilizing various animal models and combinatory
models to determine the most effective way to treat TBI in humans. Patients with a combination
of TBI and acute respiratory distress syndrome (ARDS) have symptoms of intracranial
pressure, cerebral perfusion pressure, partial pressure of carbon dioxide in the blood (PaCO2),
and fractional inspired oxygen [23]. High-frequency oscillation (HFO) and tracheal gas
insufflation (TGI) were found to ameliorate gas-exchange and alleviate the pressures caused
by these symptoms [23]. Studies suggest monitoring beyond intracranial pressure symptoms
by using the brain tissue oxygenated pressure (PbtO2) targeted therapy, transcranial doppler,
and cerebral microdialysis to individualize treatment plans of TBI patients [24]. A link between
Alzheimer’s disease (AD) development and post-TBI in humans is being hypothesized due to
ongoing research. Cleavage of amyloid precursor protein (APP), which produces amyloid-β
(Aβ) peptide, is a common hallmark in AD. At autopsy, TBI patients have reported Aβ peptides
and neurofibrillary tangles of hyperphosphorylated tau proteins, thus leading to the hypoth‐
esis that AD can possibly be a secondary effect of TBI [25]. A past study showed that an increase
of neuronal C5a receptors and C5b-9 terminal complex, a promoter of the cell cycle and cell
lysis, in diffuse axonal injury (DAI) of TBI, could lead to possible secondary neuronal cell death
[26, 27]. New studies show that the C5a receptors and C5b-9 terminal complex should be used
as targeted treatment areas, but are not necessarily a source of secondary axotomy in DAI [28].
Alternate studies have utilized medication to treat and prevent secondary insults due to the
TBI. Progesterone, a cholesterol derived hormone, has been used in rat and human models as
a neuroprotectant [29]. Progesterone (PROG) is converted into allopregnanolone (ALLO),
which is beneficial to an injured brain. Although it is unknown how the PROG metabolic
process assists in the recovery of TBI patients; progesterone is one of the first applicable
medicinal treatments for TBI in humans [29]. The ProTECT III study has reached human
clinical trials for progesterone treatment in traumatic brain injuries [30]. The ProTECT program
has shown great benefits of progesterone as a neuroprotective agent due to its ability to enter
the blood brain barrier quickly to decrease damage, downregulate inflammation, and limit
inclusive cellular necrosis, apoptosis, and cerebral edema [31, 32]. This program has been
carried out in several medical institutions including Emory University, University of Ken‐
tucky, and The Ohio State University. A useful tool for monitoring TBI in human patients is
the time-resolved optical method [33]. This method is used to obtain data regarding reflected
photons and fluorescence signals with indocyanine green (ICG) to determine brain perfusion
in TBI patients [33]. During this optical method study researchers were able to differentiate
between healthy patients with TBI [33]. As the science behind human studies of TBI becomes
progressively clearer, increasing animal model studies are developing promising results. With
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the collaboration of scientists, clinical studies representatives, statisticians, and induced TBI
studies, therapies used to fight TBI will continue to move in a positive direction.
4. Neurosteroids
The nervous system is capable of synthesizing its own reservoir of steroids, termed neuroste‐
roids due to their origins, both independently of serum steroid levels as well by utilizing serum
steroids. These were first observed by Baulieu in 1981 [34, 35]. Using cholesterol as a starting
material, endogenous steroid production in the brain and other organs amounts to a highly
involved pathway map of enzymatic action employing a number of cytochrome P450 enzymes
among others. Overall, this biosynthesis pathway is called neurosteroidogenesis (Figure 1).
The majority of these steroidogenic enzymes are expressed at different locations around the
nervous system and at multiple sites within neurons, indicating that a high amount of
coordination is involved in neurosteroid production [36]. This amount of coordination
highlights the importance of regulating such highly potent compounds. The pervasive
functions of neurosteroids involving binding and modulating neurotransmitter receptor, in
addition to influencing the genome via nuclear steroid receptors, implicate neurosteroids in a
number of neurological processes and thus possible candidates for post-injury treatment of
traumatic brain injury (TBI) [29, 36].
Figure 1. Pathway of neurosteroidogenesis and neurosteroidogenic enzymes. Cholesterol is initially converted into
pregnenolone. Neurosteroids are then synthesized from pregnenolone through different pathways involving various
enzymes. P450scc, mitochondrial cholesterol side chain cleavage enzyme, mediates c20-hydroxylation, 22-hydroxyla‐
tion, and scission of the c20–22 bond; P450c17, mitochondrial 17-hydroxylase, mediates 17α-hydroxylation and scis‐
sion between c17-20 bond; P450c 21, mitochondrial 21-hydroxylase, mediates 21-hydroxylation; P450aro,
mitochondrial aromatase, mediates two 19-hydroxylations and one 2-hydroxylation; P450c11β, mitochondrial 11β-hy‐
droxylase, mediates 11-hydroxylation; P450c11AS, mitochondrial aldosterone synthase, mediates c11,18-hydroxyla‐
tion and 18-oxidation; P450c11B3, the third mitochondrial 11β-hydroxylase, mediates 11β and18-hydroxylation; 3β-
HSD, 3β-hydroxysteroid dehydrogenases, mediates both 3β -hydroxysteroid dehydrogenase and D5-D4-isomerase
activities; 17β-HSD, 17-ketosteroid reductase (KSR), mediates c17β reduction or c17 oxidation; HST, sulfotransferase,
mediates 3β-hydroxylation with sulfate groups; STS, sulfatase, hydrolyzes sulfate groups at 3β.
A number of neurotransmitter receptors are modulated by neurosteroids, including the γ-
aminobutyric acid (GABAA), N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-meth‐
yl-4-isoxazolepropionic acid (AMPA), kainate, glycine, 5-hydroxytryptamine (5-HT3 or
serotonin), sigma type 1 (σ1), nicotinic acetylcholine, and oxytocin receptors, and the modu‐
lation can be positive or negative depending on the steroid identity [36]. Although some
steroids produced in other endocrine organs are still found in the brain, the physiological role
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and significance of neurosteroids are different in the brain. Neurosteroids affect the develop‐
ment, structure, and function of the central nervous system. This diverse population of
neurotransmitter receptors illustrates how influential neurosteroids are on the brain. The
complexity of these interactions is illustrated by considering how similar steroid structures
can have different effects on the same receptor and how these minor structure alterations are
tightly regulated. In particular, the neurosteroids progesterone, dehydroepiandrosterone
(DHEA), pregnenolone, and allopregnenolone (ALLO), illustrated in Figure 2, are potential
post-TBI therapeutic candidates due to their roles in various aspects of neurogenesis and the
repair and survival of neurons [37].
Figure 2. Progesterone (A), dehydroepiandrosterone (B), pregnenolone (C), and allopregnenolone (D) are potentially
beneficial neurosteroids for the treatment of TBI.
DHEA promotes axonal growth and functional activity of specific neuronal networks, while
ALLO can induce axonal regression in the developing hippocampus. Progesterone can
regulate myelin formation, improve the myelination of injured nerves in vivo, facilitate
myelination in vitro, and induce oligodendrocyte maturation in vitro. Moreover, neurosteroids
can modulate neuronal excitability and activity by interacting with different types of receptors.
There are mainly two different action mechanisms that neurosteroids undergo to carry out
their biological functions in the brain: genomic actions and nongenomic actions. Genomic
actions are mediated by nuclear steroid receptors, such as progesterone, glucocorticoid, and
mineralocorticoid receptors, while nongenomic actions are mediated by neurotransmitter
receptors, such as GABAA, N-methyl-D-aspartate (NMDA), and sigma receptors. Classical
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nuclear steroid receptors regulate gene transcription so it is a long-term process. PROG binds
both to progesterone and neurotransmitter receptors. Corticosterone binds to glucocorticoid
receptors with a low affinity, while both corticosterone and aldosterone bind to mineralocor‐
ticoid receptors with a high affinity. However, the acute effects of neurosteroids are not related
to nuclear steroid receptors, but the majority of neurosteroids interact with neuronal mem‐
brane receptors and ion channels [38].
As positive modulator(s) of the GABAA and kainate receptors and negative modulator(s) of
the glycine, 5-HT3, nicotinic, acetylcholine, and oxytocin receptors, progesterone and its
derivatives could play potential roles in neuroregeneration involving reducing inflammation,
helping remyelinate neurons and reducing inflammation [36, 37]. In part by negatively
modulating the GABAA receptor and positively modulating the NMDA and σ1 receptors,
DHEA and its sulfate derivative (DHEAS) promote dendritic growth and branching and form
synapses as well as help with memory [36]. DHEA protects against oxidative damage in
hippocampal neurons and glutamate toxicity by inhibiting nitric oxide synthase and G-
protein-coupled receptors that activate cell-survival pathways [39-41]. Pregnenolone sulfate
is a negative modulator of GABAA, kainate, AMPA, glycine, and σ1 receptors and a positive
modulator of NMDA receptors that has no effect on 5-HT3 receptors, helping this neurosteroid
play an important role in benefiting memory [36]. ALLO, a potent positive allosteric modulator
of GABAA, binds to discrete site on the GABAA receptor, thereby increasing the mean open
time and decreasing the mean closed time of the channel, resulting in the increase in the
chloride current through the channel and consequently in a reduction of neuronal excitability.
NMDA receptors exhibit at least two distinct sites for neurosteroid modulation, mediates the
effects of either positive or negative modulators. A significant number of studies have shown
the neuroprotective effects of neurosteroids against many pathologic conditions (Figure 3).
PROG and ALLO reduce cell damage and improve outcomes of focal ischemia in a stroke
model [42]. Allopregnenolone, while contrasting pregnenolone’s benefits on memory, does
help relieve anxiety [36]. Many studies focus on the neuroprotective role of estrogen specifi‐
cally in the hippocampus and as it improves cognitive function against disease, aging, and
stroke, mitigating cell death and stimulating neuronal proliferation in the hippocampus and
other structures [43]. Testosterone also shows a neuroprotective effect, but it is partly due to
its conversion to estrogen in the CNS [44]. Testosterone protects primary human fetal neurons
against serum-deprivation-induced cell death and oxidative stress through androgen recep‐
tors [45, 46].The structures for these described neurosteroids can be seen in Figure 3.
Neurosteroids can affect brain function by not only interacting with neurons, but also acting
on glia cells, such as microglia, Schwann cells, oligodendrocytes, and astroglia. By acting on
microglia and Schwann cells myelination is modulated, while acting on oligodendroglia and
astroglia the response of nerve tissue to pathological insults is altered. Specifically, the effect
of neurosteroids on astroglia is crucial because astroglia play critical roles both in the central
nerve system (CNS) and neural signaling by regulating extracellular ion concentrations and
local cerebral blood flow, and by modulating synaptic transmission and plasticity [35]. Due to
their wide variety of influences on important neurotransmitter receptors, neurosteroids have
a large potential benefit for neuronal protection and repair following TBI. The various roles of
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neurosteroids such as progesterone, dehydroepiandrosterone, pregnenolone, and allopreg‐
nenolone give them special consideration as post-TBI therapeutics, and progesterone research
in particular is offering promising results [29, 37, 47]. Studies in rodents and humans have
shown beneficial effects of PROG on both mortality and functional outcomes following TBI by
its neuroprotective effect [48]. In addition to PROG, its metabolite, ALLO also has shown
beneficial effects equal to or in excess of those of PROG in TBI by modulating the GABAA
receptor, not classic nuclear receptors [29]. Both PROG and ALLO have beneficial effects in
reducing blood-brain barrier dysfunction and intracranial pressure following TBI, and also in
reducing brain swelling and edema that are associated with TBI [49]. DHEAS and its analog,
fluasterone (DHEF), can also improve recovery of function in male rats after TBI [50, 51]. These
findings altogether bolster the neuroprotective effects of neurosteroids and their analogs
thereby, leading to plausible future therapeutic strategies in the clinical treatment of TBI.
Figure 3. Chemical structure of cholesterol and neurosteroids. Cholesterol (A) is converted into various neurosteroids
(B). Each neurosteroid has significant roles in the brain and nerve system, but these neurosteroids, specifically, have
shown neuroprotective properties.
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5. Flavonoids
Secondary events following a traumatic brain injury (TBI) account for the majority of neuro‐
degeneration, beginning within the first hour post-TBI and lasting for days [52]. The elevation
of ROS levels within neurons has been recognized as an early event following TBI occurring
within minutes [53].The overproduction of ROS due to TBI cannot be eliminated by the limited
amount of antioxidants, leading to oxidative stress, one of the most common secondary injury
mechanisms. These remaining ROS begin to interact with proteins, lipids, carbohydrates,
nucleic acids, or signaling molecules. The oxidative modification of neuronal molecules
changes their structures and function as well as signaling pathways, subsequently leading to
irreversible neuronal inflammation, dysfunction, and death. Due to the initial rush of rapid
superoxide (O2.-) production during the first hour and the shift to a pro-oxidant environment
that occurs as early as 3 hours post-TBI, free radicals play an integral part in the initial events
following a TBI and continue to react with cellular components for several days, with their
prevalence peaking between one and two days after the initial injury [52-54]. As revealed by
Ansari, et al. there is a narrow window of opportunity for post-TBI therapeutic intervention
due to this shift towards an oxidative environment [54]. Thus, supplementing the brain with
substances having potent antioxidant capacities, such as flavonoid compounds, as early as
possible could be a beneficial treatment for mitigating the otherwise inevitable cascade of
secondary damage.
The flavonoid class of compounds describes molecules that share one of the three similar
backbones illustrated in Figures 4 and 5. Flavonoids are polyphenolic compounds with a
diphenylpropane skeleton which consists of two aromatic rings, (A ring and B ring) bound
together by three carbon atoms (C1, C2, and C3) forming an oxygenated heterocycle (C ring) as
depicted in Figure 5A. These compounds are divided into six major classes depending on their
saturation and the number and arrangement of either the carbonyl group or hydroxyl groups
in the C ring (Figure 5B). Flavanones contain a carbonyl group at C3, flavones have a carbonyl
group at C3 and a double bond between C1 and C2, isoflavones have a carbonyl group at C3, a
double bond between C1 and C2, but the B ring is connected to C2 instead of C1, flavanols contain
a hydroxyl group at C2, while anthocyanidins have a hydroxyl group at C2, one double bond
between oxygen and C1 and another between C2 and C3, lastly flavonols have a carbonyl group
at C3 and a hydroxyl group at C2. Furthermore, there are a variety of flavonoids present within
each group due to the differences in the number and arrangement of hydroxyl group in the A
and B rings in the structure (Figure 5B). The relative antioxidant ability of individual flavonoids
to scavenge ROS is correlated with these different chemical structures [55]. The unsaturation
of the C ring enhances the scavenging ability of flavonoids by increasing their stability via
electron delocalization. The effects of the number and the arrangement of these hydroxyl
groups also affect antioxidant activity. For example, the absence of a hydroxyl group at C2 of
the C ring decreases the activity, while the presence of two hydroxyl groups in the ortho-
diphenolic arrangement in the B ring increases the activity against superoxide anion. In
addition, the presence of a catechol group also enhances the ability against peroxynitrite
scavengers, because catechol can afford a two-electron reduction of peroxynitrite to nitrite
coupled to their oxidation to the corresponding o-quinones [56].
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Figure 4. The flavone (A), isoflavan (B), and neoflavonoid (C) structures serve as the chemical backbones for flavonoid
compounds.
Figure 5. Chemical structure of flavonoids. Basic chemical structure (A) and six classes (B) including: flavanones, fla‐
vones, isoflavones, flavanols, anthocyanidins, and flavonols.
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Many natural flavonoids can be found in plant material such as fruits, vegetables, and plant-
derived beverages, such as green or black tea. Once introduced into the body, flavonoids are
converted into their metabolites which can have substantially different bioactivity properties.
These structures have been well established as antioxidants that reduce oxidative stress not
only by directly scavenging reactive oxygen species (ROS), but also by increasing the activity
of antioxidant enzymes or decreasing the activity of redox enzymes respectively [57]. More‐
over, flavonoids can modulate cellular homeostasis helping to reduce inflammation and cell
toxicity [57].These compounds have neuroprotective properties in addition to their abilities to
scavenge free radicals [34, 58, 59]. Due in part to the these properties and the abilities of certain
flavonoids to cross the blood-brain barrier (BBB), flavonoids appear to be excellent treatment
opportunities for TBI models [59]. Indeed, extensive therapeutic use of flavonoids and similar
polyphenolic compounds post-TBI have proven this to be true, with these compounds serving
to remedy many TBI-induced maladies such as edema, neuroinflammation, cognitive and
neuronal functions, cell survival, oxidative stress, and cellular energy homeostasis [60-63].
Catechin, epicatechin, and epigallocatechin gallate (EGCG), chemicals all found in green tea
(Figure 6A), reduce the production of nitric oxide and hydrogen peroxide, lipid peroxidation,
and DNA oxidation induced by ischemia/reperfusion in rats [64]. Several flavones including
baicalein, baicalin, and wogonin (Figure 6B) components of the Scutellaria plant, reduce lipid
peroxidation and nitric oxide production in the cortex and hippocampus of rats as well as
inhibit pro-inflammatory cytokines [65]. The down-regulation of the NFkB pathway confirmed
with medicinal extracts rich in flavonoids, such as Crataegus, orally administrated and
protected the brain against delayed cell death by increasing the levels of antioxidants in the
brain, Ginkgo biloba extract (EGb 761) [66]. It has been well documented that metabolites of
flavonoids also have neuroprotective properties. The death of both cortical and striatal neurons
induced by oxidative stress has been shown to be inhibited by the methylated metabolite of
epicatechin with a protection capacity similar to epicatechin [67]. Specifically, caffeic acid has
shown neuroprotective properties and is a component of a patented mixture of flavonoid
compounds, known as Pycnogenol® (PYC), which has produced very promising results in rat
models of TBI [58, 68].
Based on studies showing that flavonoids have potent neuroprotective and anti-inflammatory
properties, there are several recent studies in which flavonoids were used as post injury
therapeutic strategies for TBI. These include epicatechin, wogonin, baicalein, and pycnogenol.
Water containing EGCG, a major component of green tea possessing strong antioxidant
properties, was given to rats after TBI and demonstrated the ability to inhibit free radical
induced degradation that have the potential to differentiate into neurons and glia around the
injured area [69]. The effects of wogonin and baicalein, flavonoids possessing potent anti-
inflammatory properties, were investigated on mice or rats subjected to controlled cortical
impact injury as post-injury treatments [61]. Their neuroprotective effects were suggested
because they improve functional and histological outcomes, and reduced induction of pro-
inflammatory cytokines. Prior to its use in TBI models, the bioflavonoid, PYC has exhibited
various antioxidant properties as well as the abilities to prevent neurotoxicity and apoptosis
[54, 70-74]. Scheff, et al. recently reported a number of benefits from post-TBI intraperitoneal
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administration of PYC in rat models, including an increased presence of endogenous antiox‐
idants in the hippocampus and cortex at 48 hours post-TBI, increased GSH:GSSG ratio in both
regions at 48 hours post-TBI, and increased synaptic proteins at 96 hours post-TBI [58]. The
neuroinflammatory cytokines interleukin-6 and tumor necrosis factor α were also significantly
decreased at 48 hours post-TBI using this treatment. Because of the substantial amount of free
radical-induced oxidative damage that occurs post-TBI, these increases in antioxidants and
decreases in inflammatory markers not only highlight the benefits of the particular mixture of
flavonoids in PYC, but also serves to further evidence the abilities of flavonoids in general to
help re-establish the balance of antioxidants and oxidants to offset the development and
progression of oxidative stress post-TBI.
Flavonoids such as those found in PYC offer a unique approach to TBI treatment, which aims
to remedy the initial post-TBI cascade of oxidative damage and early decreases in antioxidant
capacity. PYC has helped to prove the potential of flavonoids in mitigating the secondary
events of TBI by supplementing the brain with antioxidants that cross the BBB. Because the
initial injury of TBI is virtually untreatable, therapeutic intervention within the first three hours
post-TBI with compounds such as flavonoids offer promising insight into treatments that will
result in future clinical significance.
Figure 6. Flavonoids possess neuroprotective properties and therapeutic effects in TBI. Flavanols, such as catechin, epi‐
catechin, and epigallocatechin gallate (EGCG), found in green tea (A). Flavones, such as baicalein, baicalin, and wogo‐
nin, are found in celery (B).
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6. Statins
Statins are a class of drugs that inhibit 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA)
reductase, the rate-limiting enzyme in the endogenous production of cholesterol, as illustrated
in Figure 7. As such, statins are prescribed to lower serum cholesterol levels in patients for the
purpose of preventing heart disease. However, a number of benefits of statin use have also
been reported for the treatment of traumatic brain injury (TBI) which are not related to lower
cholesterol levels, including increasing synaptogenesis and angiogenesis, increasing neuronal
survival, improving cognitive abilities, and decreasing lipid peroxidation, among others
[75-77]. This versatility of statins gives them unique advantages over other potential treatments
for TBI that are specialized for only certain injury-related symptoms [76].
Figure 7. HMG-CoA reductase catalyzes the rate-limiting step of cholesterol formation (A). The structure for simvasta‐
tin, a statin drug that inhibits HMG-CoA reductase to decrease endogenous cholesterol synthesis (B).
Most of the neurodegeneration that results from a TBI is generated over the days following
the initial insult [52]. The events causing this neurodegeneration, collectively referred to as the
secondary injury, offer several opportunities for therapeutic intervention. There are currently
no approved therapeutic treatments for TBI, so care is limited to non-chemotherapeutic
methods of supporting normal cranial pressure and cerebral perfusion [6]. Because the primary
injury of TBI creates a contusion around which cerebral blood flow is significantly limited,
there is a high potential for ischemia and thus infarction as a secondary injury [78, 79]. In
addition, many microscopic inflammatory processes are mediated largely by oxidative stress
from excess free radical formation, which occurs in significant amounts within the first hour
post-injury [52, 53]. Thus, because of the many benefits of statin use on endothelial function
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and the role(s) of statins in preventing oxidative stress, this avenue of research offers significant
promise for TBI treatment [80, 81].
Since Lu, et al. first began investigating the therapeutic potential of statins in 2004, a growing
body of evidence illustrating the neuroprotective effects of statin use in both pre- and post-TBI
treatment has been established [75, 77, 82-85]. However, the exact mechanism(s) by which
statins execute this neuroprotection is not completely understood. Statins are known to
provide many benefits to endothelial function independent of cholesterol levels, many of
which involve nitric oxide (NO), a second messenger molecule deeply rooted in signaling
pathways related to endothelial functions. These NO–related functions of statins include both
upregulating and triggering activation of the enzyme endothelial NO synthase (eNOS),
recovering eNOS function when oxidized low density lipoprotein is present, and recovering
eNOS function during hypoxia [86-88]. Studies aimed at elucidating the exact mechanisms
underlying the relationship between statins and eNOS have determined that inhibiting the
synthesis of mevalonate has downstream inhibitory effects on the isoprenylation of the Rho
protein, a member of a multifunctional family of GTPase proteins [89, 90].
As the direct relationships between statins, Rho, and eNOS begin to unravel, the importance
of statins in potential post-TBI treatment will likely increase. Statins differ in their lipophilic
properties, HMG-CoA reductase binding abilities, and their abilities to cross the blood-brain
barrier (BBB), which will make the search for an ideal post-TBI candidate very involved.
Simvastatin, depicted in Figure 7B, has proven useful in TBI treatments due in part to its BBB
penetration, leading to significant benefits on BBB permeability, cerebral edema, and learning
and memory [83, 91].
7. Gamma-glutamylcysteine Ethyl Ester
Glutathione (γ-glutamylcysteineglycine), illustrated in its reduced (GSH) and oxidized (GSSG)
forms in Figure 8, plays a key role in cellular defense and repair, where it serves to maintain
intracellular redox status by conjugating toxic species for export, regulating the activities of
redox-sensitive enzymes, and neutralizing oxidative species via antioxidant enzyme mecha‐
nisms [92]. To highlight the significance of these responsibilities, glutathione exists at milli‐
molar concentrations in the cell and its reduced state is carefully maintained to keep the
GSH:GSSG ratio high [93]. The combination of high polyunsaturated fatty acid content, high
oxygen respiration and glucose metabolism, and relatively low antioxidant capacity in the
brain establishes an environment that is highly susceptible to oxidative stress. Thus, because
the brain is not adequately prepared to defend against the almost immediate surge of reactive
oxygen species (ROS) formation that is brought about by a traumatic brain injury (TBI),
utilizing the native antioxidant mechanisms of the brain by increasing glutathione availability
is a treatment route whose ability to curb initial inflammatory processes in the brain appears
very promising [94, 95].
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Figure 8. Glutathione can exist in its reduced form (A) and oxidized form (B) at physiological pH.
Synthesis of glutathione, illustrated in Figure 9, occurs in a two-step mechanism where
glutamate and cysteine are first covalently bound via γ-linkage to produce γ-glutamylcysteine
(γ-GC) by the enzyme γ-glutamylcysteine synthetase, and then glycine is covalently bound to
γ-GC via α-linkage to cysteine by the enzyme glutathione synthetase. This mechanism offers
a prime opportunity to increase glutathione synthesis since regulation only occurs at the first
step. Glutathione is a feedback inhibitor of γ-glutamylcysteine synthetase, prohibiting excess
production of γ-GC. This step is also rate-limited by the availability of cysteine, whose
intracellular concentration is lower than the concentrations of glutamate or glycine. However,
glutathione synthetase is not inhibited by glutathione, so glutathione concentrations can be
increased when excess γ-GC is supplemented [93]. In fact, intracerebroventricular adminis‐
tration of γ-GC increases brain glutathione content more so than intracerebroventricular
administration of GSH ethyl ester or intraperitoneal administration of cysteine in rats [96]. The
γ-GC analog, γ-glutamylcysteine ethyl ester (GCEE), shown in Figure 9B, has also proven to
be an excellent candidate for supplementing intracellular γ-GC availability by increasing
glutathione concentrations, and has been shown to decrease markers of oxidative stress both
in vitro and in vivo [95, 97-99].
Various models of TBI have offered valuable insight into the mechanisms by which the brain
incurs substantial damage following traumatic injury. Following the initial TBI injury,
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secondary events can occur for days post-injury and these events account for the majority of
TBI-induced neurodegeneration [52]. Due to the role of the superoxide radical (O2.-) in creating
an oxidative stress environment, the significant production of O2.- in cat brain during the first
hour following a fluid percussion model of TBI implicates free radical-induced oxidative stress
in early mechanisms of TBI secondary injury [53]. The large capacity of GSH for detoxifying
reactive oxygen species (ROS) and reactive nitrogen species (RNS), which are produced
directly from native reactions of O2. - with various intracellular components, emphasizes the
importance of maintaining adequate GSH availability during such rapid increases in O2.-
production. Indeed, GSH availability is significantly decreased at 2 hours and even 24 hours
post-injury using a rat model of blast induced mild TBI [1]. By replenishing GSH reserves via
bypassing native feedback inhibition of GSH synthesis, GSH becomes available when it is
needed most following TBI, and GCEE treatment post-TBI has so far proven to be very
favorable by decreasing protein nitration, decreasing autophagy, and decreasing blood-brain
barrier permeability [95, 100, 101].
In contrast to the various beneficial mechanisms of ROS and RNS scavenging and detox by
glutathione, it is also worth noting that GSH can react directly with O2.- to produce the
glutathione radical (GS∙), which can abstract hydrogen atoms polyunsaturated fatty acids,
carbohydrates, and peptides [102-105]. Also, mitochondrial manganese superoxide dismutase
Figure 9. The enzymes γ-glutamylcysteine synthetase (1) and glutathione synthetase (2) synthesize glutathione in a
two-step mechanism (A). The γ-glutamylcysteine analog γ-glutamylcysteine ethyl ester can increase glutathione syn‐
thesis (B).
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(Mn-SOD) is known to be a better scavenger of O2. - than GSH and should thus limit the amount
of GS∙ formed, but the activities of Mn-SOD and copper/zinc-SOD (Cu/Zn-SOD) are at their
minimums at 24 hours post injury in the ipsilateral hippocampus of rat brain following a
cortical contusion model of mild TBI and stay decreased for several days post-injury [54, 105].
Indeed, the presence of the lipid peroxidation product 4-hydroxynonenal (HNE) is signifi‐
cantly elevated as protein-bound HNE in a TBI rat model, and post-TBI treatment of GCEE
does not decrease its presence [95].
Post-TBI treatment and treatment of oxygen-glucose deprivation, a possible effect of ischemia,
with GCEE have proven to be very beneficial, offering promising avenues of TBI research to
determine how these effects translate into ameliorating clinical symptoms [95, 101]. While
glutathione does have the potential to cause lipid peroxidation and models have yet to show
a beneficial effect in this regard, increased glutathione availability via post-TBI treatment with
GCEE has been shown to significantly decrease the presence of nitrated and carbonylated
proteins, which are known to be formed by peroxynitrite (ONOO-), a product of O2. - reacting
with nitric oxide (NO) in the presence of carbon dioxide [95, 104]. In vitro models using
synaptosomes indicate that up regulated glutathione synthesis via GCEE administration can
detoxify ONOO- directly [97]. However, due to the reaction of GSH and O2. - in forming GS∙,
there is also potential for a trade-off of ROS formation that allows unreacted NO to carry out
its beneficial endothelial functions: elevated glutathione could potentially out-compete NO for
reacting with O2.-, increasing lipid peroxidation but allowing NO to promote blood flow and
thus encourage neuron survival [81, 106]. Because glutathione has the potential to cause lipid
peroxidation but is also known to export products of lipid peroxidation, such as HNE, out of
the cell via multidrug resistant proteins, the lack of a significant increase in protein-bound
HNE levels in GCEE-treated rats post-TBI could be a result of this trade-off. While further
studies are required to determine the exact mechanisms and therapeutic significance of GCEE
treatment post-TBI, the many functions of glutathione and initial positive results indicate a
high therapeutic potential for this compound [92, 95, 101].
8. Histone deacetylase inhibitors
Treatment of traumatic brain injury (TBI) using histone deacetylase inhibitors (HDACi) is a
relatively new therapeutic strategy that has so far provided some very encouraging results for
invoking neuroprotective mechanisms via epigenetic changes. By inhibiting histone deacety‐
lase, HDACi suppress the removal of acetyl groups from histone lysine residues, freeing DNA
segments for transcription. Like statins, the exact mechanisms by which these compounds
provide benefits in TBI models are largely unknown. This could be due in part to the large
number of proteins affected by such epigenetic changes as well as the intricate relationships
between affected proteins and cognition, although the development of novel HDACis is
beginning to shed light on proteins of particular importance such as nerve growth factor (NGF)
and heat-shock protein 70 (HSP70) [6].
Epigenetic changes are chemical modifications to the genome changes that result in altered
gene regulation. These epigenetic changes occur throughout one’s life due in part to environ‐
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mental interactions [107, 108]. Following such a drastic change to one’s internal environment
as that which results from a TBI, it should be expected that one’s epigenetic profile would
change accordingly. Indeed, TBI results in substantial epigenetic changes, resulting in
increased transcription of several proteins involved in pro-survival pathways and anti-
apoptotic pathways [6]. Epigenetic changes in the hippocampus histone-H3 have been found
to occur for the first days after a pediatric rat model of TBI, during the same time frame that
the secondary injury of TBI is known to occur [52, 109]. Changes in gene regulation are key
responses to TBI, and like statins, HDACis are novel therapeutics that can treat several
consequences of a TBI at once [6, 110].
Gene arrays of TBI models indicate that there are substantial changes to the gene expression
following injury [1, 111-113]. Post-TBI treatment with the HDACi LB-205 was able to increase
histone-H3 acetylation, a key histone that has been found to have reduced acetylation follow‐
ing TBI, at safer therapeutic doses than a previously employed therapeutic. In addition, the
up regulation of pro-survival proteins nerve growth factor (NGF), p-TrkA, p-AKT, NF-kB, and
Bcl-2, as well as down regulation of pro-apoptotic proteins p-JNK, BAX, and p75(NTR) were
results of post-TBI LB-205 treatment [6]. Of particular importance to neuron survival is the up
regulation of NGF. This neuropeptide is essential to the survival of specific neurons and could
help with regeneration of neurons post-TBI as higher CSF levels of NGF are associated with
better clinical outcomes following TBI [114-119]. While further research into the potential
therapeutic uses of HDACis for treatment of TBI is necessary to fully understand their clinical
value, current understanding of post-TBI gene regulation and initial testing of HDACis such
as LB-103 have uncovered a multifunctional treatment opportunity that may prove to be of
significant importance in the future [1, 6].
9. Enzyme kinetics and TBI
Enzyme kinetics focuses on chemical reactions that are catalyzed by enzymes. Enzymes are
proteins that alter other molecules by forming an enzyme-substrate complex, transforming the
initial substrate bound to the active site of the enzyme into a product via an enzymatic
mechanism in which the enzyme is not consumed within the catalyzed reaction. Enzymes do
not alter the equilibrium position of a reaction, but continue to increase the reaction rate as the
substrate concentration of the respective enzyme increases until all active sites of the enzyme
are saturated. From this point, the reaction rate will depend upon the turnover rate of the
enzyme. Numerous enzymes bind to one substrate and produce a single product. However,
many enzymes are capable of binding to multiple substrates. Kinetic studies on single-
substrate binding enzymes can typically show measurements of enzyme affinity to substrate
binding, as well as turnover rate. Kinetic studies on multi-substrate binding enzymes usually
can show substrate binding sequences, as well as product release sequences. There is typically
one rate-determining step that indicates overall kinetics of the enzyme, which could include
a conformational change or chemical reaction. Enzyme kinetics can be used to measure the
reaction rate of a diverse range of processes for investigation of varying conditions in an
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experimental design. Enzyme kinetics can uncover metabolic roles, control mechanisms,
catalytic mechanisms, and how a drug/agonist may inhibit an enzyme.
10. Alteration of energy metabolism
Alteration of energy metabolism in specific enzymatic reactions involving varying conditions
of oxidative stress placed on the enzymes following moderate traumatic brain injury (TBI) has
been investigated as possible biomarkers of moderate TBI, which can be observed by enzyme
kinetics. Moderate TBI is a common source of oxidative stress in biological systems, caused by
secondary damage due to the presence of reactive oxygen and nitrogen species (ROS and RNS,
respectively). This leads to a decrease in overall antioxidant capacity [120, 121]. This oxidative
stress can disrupt protein structure, leading to a loss of function. The body can attempt to
prevent or overcome this event in numerous ways including the use of antioxidants and
epigenetic factors. Antioxidant enzymes that are found to be more active following TBI include
catalase and glutathione peroxidase. Catalase catalyzes the decomposition of hydrogen
peroxide to water and oxygen (Figure 10), while glutathione peroxidase reduces hydroperox‐
idases to their respective alcohols (including the conversion of hydrogen peroxides to water),
using reduced glutathione as a cofactor, which will be oxidized to glutathione disulfide (Figure
11). Catalase was found to have a threefold increase, while glutathione peroxidase had a
twofold increase in a time course study reflecting temporal increase in nerve growth factor
(NGF) following a cortical contusion model [122]. Enzyme activity levels of energy-producing
enzymes such as enolase and creatine phosphokinase are of interest as possible indicators of
moderate TBI. Enolase and creatine phosphokinase both play significant roles in energy
production. Enolase, an integral part of the glycolytic pathway, is highly expressed in neuronal
cytoplasm. It converts 2-phosphoglycerate to phosphoenolpyruvic acid (Figure 12). Neuron-
specific enolase, found only in the brain, can be used for the possible detection of neuronal cell
death with high sensitivity and specificity. Increased cerebrospinal fluid (CSF) and serum
levels of enolase are associated with TBI and could be used to gauge the degree of injury. This
finding could play a key role in future research, as upregulated proteins after TBI injury are
typically identified as possible diagnostic biomarkers [123]. S100β proteins, a component of
astroglia and Schwann cells, are known to increase post-injury in CSF and serum. Creatine
phosphokinase can act as an energy reservoir for rapid buffering of ATP concentration in cells,
as well as an intracellular mode of energy transport via a creatine phosphokinase shuttle circuit
[124]. Creatine phosphokinase acts by converting creatine to creatine phosphokinase (Figure
13). Creatine kinase isoenzyme BB (CK-BB), neuron specific enolase, and S-100β proteins have
been widely studied as biochemical serum markers of TBI. It has been suggested that CK-BB
sensitivity and specificity is inadequate for use as a TBI indicator [125]. It is also suggested that
serum levels of neuron specific enolase do not correspond to the extent of TBI damage, most
likely due to a long half-life of 20 hours. S-100β serum levels have correlated to injury severity
in several studies [125].
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Figure 10. Catalase enzymatic reaction.
Figure 11. Glutathione peroxidase enzymatic reaction.
Figure 12. Enzymatic reaction for enolase.
Figure 13. Enzymatic reaction for creatine kinase.
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Numerous other proteins such as enolase are known to be upregulated post-injury including
C-reactive proteins, transferrin, and breakdown products of collapsin response mediator
proteins (CRMP-2), synaptotagmin, and α2-spectrin. C-reactive proteins bind phosphotidyl‐
choline on the surface of dead cells, which is a sign of inflammatory response. Transferrin, an
iron-binding glycoprotein, transfers iron from transferrin receptors on the surface of cells to
cytoplasmic regions. Expressed in the nervous system, CRMP-2 is essential for axon formation
from neurites and growth cone guidance. As a result of trauma, the protease calpain targets
CRMPs for cleavage. Both calpain and caspase-3 proteases cleave α2-spectrin, indicating
necrotic and apoptotic cell death. Synaptotagmin act as a calcium sensor throughout the brain,
thereby monitoring calcium homeostasis. In brain-specific systems biology analysis, over 320
proteins have been found to be upregulated 24 hours post-injury in a penetrating ballistic-like
brain injury model (PBBI). The majority of these proteins are involved in protein metabolism.
These proteins are essential in neurite outgrowth and cell differentiation. Calcineurin, also
known as protein phosphatase 3, is a calcium-stimulated phosphatase. It was significantly
increased in post-injury hippocampal and cortical homogenates of a moderate, central fluid
percussion TBI injury model for 2-3 weeks post-injury. Substrate affinity was not changed, but
maximal dephosphorylation rate did increase [126]. The increased rate has many physiological
consequences, resulting in a greater possibility of neuronal cell death. Enolase, phosphogly‐
cerate mutase, and ATP synthase are nitrated in TBI and all are associated with energy
metabolism in the brain [127]. Phosphoglycerate mutase, a key glycolytic enzyme, catalyzes a
phosphoryl group transfer allowing 3-phosphoglycerate to be converted to 2-phosphoglycer‐
ate (Figure 14). ATP synthase provides energy to cells through the production of ATP from
ADP and inorganic phosphate. Protein dysfunction of these key enzymes can lead to an
accumulation of glycolytic intermediates in several metabolic pathways. This ultimately
signifies a reduction in pyruvate formation and overall ATP production in both cytoplasmic
and mitochondrial regions of the cell. Since ATP is such an important component of cells it
would be beneficial for the cells to upregulate ATP producing enzymes, particularly at points
where neural communication is established. The acute phase after TBI shows a regionally
heterogeneous metabolic state. The glucose transporter protein family and hexokinase
activities were studied, showing consistently reduced hexokinase activity throughout the
whole brain following contusional TBI. Overall, glucose transporter proteins appeared to only
be impaired in the immediate area around the contusion [128].
Many other candidate biomarker proteins are in the process of receiving clinical validation.
An abundance of glial fibrillary acidic proteins (GFAPs), acting as intermediate filament
proteins, can indicate damaged glia. GFAP, found only in the central nervous system, forms
a network support in astroglial cytoskeletons. GFAP serum levels have been found to increase
post-injury and rapidly decrease after the first six hours, making GFAP an ideal biomarker
due to the specificity of the protein [125]. A recent study found that cerebrospinal fluid levels
of neuron specific enolase, brain specific creatine kinase, glial fibrillary acidic protein, and
S100β were all significantly increased six hours post-TBI in a swine model [129]. These enzyme
levels then decreased 24 hours post-injury in all markers except S100β at 72 hours post-injury.
Increased tau and spectrin protein breakdown products indicate axonal damage. Other
enzymes consistently showing upregulation in post-TBI injuries include ubiquitin carboxy-
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terminal hydrolase L1 (UCHL1), tyrosine hydroxylase, and syntaxin-6. UCHL1 is a deubiqui‐
tinating protease enzyme, hydrolyzing the C-terminal bond of ubiquitin or unfolded
polypeptides. It showed significant elevation in TBI patients [130]. Calpain and caspase-3
proteases are intimately involved in necrotic and apoptotic cell death; their respective spectrin
breakdown products appear in significantly elevated levels in mortality and severe cases
involving TBI [123]. Additional mRNA expression testing has been done on caspase-1 and
caspase-3, both members of the cysteine-aspartic acid protease family. The mRNA expression
of caspase-3 was increased fivefold in the injured zone of the cortex and twofold in the injured
zone of the hippocampus on fluid percussion-induced TBI rat models at 24 hours post-injury;
caspase-1 mRNA expression is also increased to a lesser extent [131]. This suggests elevated
caspase protein activity during neuronal apoptosis.
In mitochondria, a crucial location for metabolic enzymes, moderate TBI has negative effects
on function including mitochondrial glucose utilization and oxidative phosphorylation.
Dysfunction of the cytochrome oxidase complex in mitochondrial metabolism has been
observed including cytochrome c oxidase, which is essential for oxidative phosphorylation
[121]. Cytochrome c oxidase mRNA expression was investigated in rat impact accelerator
models of diffuse TBI (DTBI), also known as “Marmarou” weight-dropping trauma models,
followed by real-time quantitative PCR assessment of tissue sections from ipsilateral and
contralateral cortex zones. Reductions of cytochrome c oxidase I, II, and III were detected in
injured cortex zones. The lowest expression was seen three days post-injury. Contralateral
cortex zones were detected to have slightly increased mRNA expression at times ranging from
six hours to seven days [121]. In vivo structural damage to the mitochondria stimulates free
radical generation, causing mitochondrial population depletion depending on injury severity.
The remaining mitochondrial population provides metabolic support that the body needs for
survival and repair [132]. This appears to be one of many complex multifunctioning mecha‐
nisms the brain is capable of in terms of neuroregeneration. It is important that nitrated and
oxidized enzymes that can be used as biomarkers for TBI, as well as upregulated or increas‐
ingly active enzymes during post-injury, continue to be explored for expansion of neurological
insight and therapeutic strategies for harmful brain injuries.
Figure 14. Enzymatic reaction for phosphoglycerate mutase.
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11. Redox proteomics and TBI
The field of proteomics encompasses the study of the proteome that provides specific details
regarding its structure and function. Proteins are vital aspects of living organisms, as they are
the primary factors of the metabolic pathways of cells. Proteomics assesses the expression level
of proteins, posttranslational modifications, and interactions of proteins within a tissue, cell,
subcellular compartment, or biofluid [123]. The objective of proteomics is to observe and
thoroughly understand the physiological processes that are occurring in normal and diseased
cells.
12. Proteins oxidatively modified by TBI
Remarkable efforts have been invested into the discovery of biomarkers of specific neurolog‐
ical disorders. Although there are no clinically validated biomarkers to diagnose TBI, several
candidate biomarkers of TBIs are being investigated and multiple studies are being conducted
to confirm these protein biomarkers as clinically accurate. Protein oxidation is the modification
of a protein induced either directly by reactive oxygen species or indirectly by reaction with
secondary by-products of oxidative stress [133]. Because proteins have many different and
unique functions, oxidative modifications of proteins can lead to diverse functional conse‐
quences. Modifications of proteins can lead to a loss of function, inhibition of enzymatic
activity, or potential risk of diseases. Kobeissy et al. identified several proteins decreased in
abundance in traumatic brain injury including, but not are limited to, collapsin response
mediator protein-2 (CRMP-2), glyceraldehyde-3-phosphate dehydrogenase, microtubule-
associated proteins MAP2A/2B, and hexokinase [134]. Upregulated proteins included C-
reactive proteins, transferrin, and breakdown products of CRMP-2, synaptotagmin, and α2-
spectrin [134]. Furthermore, ubiquitin carboxy-terminal hydrolase L1 protein (UCHL-1),
spectrin breakdown products (SBDPs), and neuron-specific enolase (NSE) are presented as the
most studied candidate protein biomarkers for TBI as neuronal and axonal protein-specific,
while glial protein-specific markers include glial fibrillary acidic protein (GFAP) and S100β
[123].
UCHL-1, a cysteine protease, hydrolyzes the C-terminal bond of ubiquitin or unfolded
polypeptides [135]. UCHL-1 is predominantly expressed in neurons, although it is also
expressed in small amounts in neuroendocrine cells [123]. Compared to control, the serum
UCHL-1 levels of TBI patients were significantly elevated after the acute phase of TBI and
beyond (> 1 week) [136]. Mondello et al., 2012 demonstrated that the parameters of UCHL-1
could be used as a biomarker for severely injured TBI patients.
α2-spectrin, primarily found in neurons, is concentrated in axons and presynaptic terminals
[137]. Upon activation in TBI, calpain cleaves the protein to SBDPs of molecular weights 145
kDa (SBDP145), 150 kDa (SBDP150), while casapse-3 cleaves α2-spectrin to a 120-kDa
(SBDP120) product. Calpain and caspase-3 are major executioners of necrotic and apoptotic
cell death, respectively, during ischemia or TBI [138-140]. SBDPs indicate calpain and caspase-3
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proteolysis of α2-spectrin, providing crucial information on the underlying cell death mech‐
anisms [123]. Elevated levels of SBDPs in CSF from adults with severe TBI were reported and
their significant relationships with severity of injury and outcome [139]. Increased CSF SBDP
levels were found to be significantly associated with mortality in patients with severe TBI. The
temporal profile of SBDPs in non-survivors was also found to be different compared to those
of survivors [140]. Taken together, these findings suggest that SBDPs may provide crucial
information not only on severity of brain injury, but also on underlying pathophysiological
mechanisms associated with necrotic and apoptotic cell death [123].
Neuron-specific enolase (NSE), a glycolytic pathway enzyme, is highly expressed in neuronal
cytoplasm. NSE has been shown to have the sensitivity and specificity to detect neuronal cell
death [141]. Increased CSF and serum levels of NSE have been reported after TBI. NSE
concentrations were also associated with severity of injury, CT scan findings, and outcome
[141-143]. Of the numerous candidate biomarkers for TBI, GFAP holds the most promise. One
of the strengths of GFAP as an ideal biomarker for TBI is that this protein is not found outside
the central nervous system [144]. GFAP, an intermediate filament protein that forms networks
that support the astroglial cells, is found only in astroglial cytoskeleton. Damage to the
astroglial cells (astrogliosis) shows subsequent upregulation of GFAP [123]. Even if the body
is subjected to multiple forms of trauma, GFAP doesn’t rise without brain injury [145, 146].
The specificity of GFAP as a biomarker makes it a formidable indicator of glial injury.
S100β is mainly found in astroglia and Schwann cells and is one of the most well established
biomarkers of brain damage [147-149]. The concentration of S100β is known to increase in CSF
and serum after injury making this protein a potential biomarker for TBI [150]. However,
S100β is not specific to the brain, as it is observed in non-nervous cells such as adipocytes,
epidermal, chondrocytes, melanoma, and Langerhans cells [151]. Furthermore, general trauma
without brain injury can increase S100β. Although a possible candidate as a biomarker for TBI,
it seems S100β is not independently accurate to determine brain damage and prognosis, but
rather in comparison to other biomarkers.
3-Nitrotyrosine (3-NT) is one of the most frequently observed byproducts from reactive
nitrogen species (RNS) reacting with proteins. As a biomarker of nitrosative stress, elevated
levels of 3-NT signify the presence of oxidative stress and decreased levels of antioxidant
enzymes [152]. The formation of RNS from oxidative stress is assumed to play a major role in
neuronal death and 3-NT is a marker for this biochemical event. Therefore, 3-NT can be utilized
as an in vivo marker of oxidative nitric oxide damage following TBI [153]. 3-NT is formed in
vivo by the reaction of tyrosine with nitrating oxidants, superoxide and nitric acid [154].
Research has shown that elevated 3-NT levels are directly related to traumatic brain injury
(TBI), protein nitration, and oxidative stress. A listing of proteins identified as being nitrated
can be seen in Table 1. The lack of consensus in the definition of mild TBI further complicates
the matter and the challenge lies in accurate diagnosis in managing post-injury [123]. The role
of 3-NT formation as an intermediate will predict the involvement of protein nitration and
oxidative stress in the brain.
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Protein Function
Synapsin 1
Regulation of axonogenesis and synaptogenesis; Encode neuronal
phosphoproteins which associate with the cytoplasmic surface of synaptic
vesicles
Gamma-enolase Neurotrophic and neuroprotective properties on a broad spectrum ofcentral nervous system (CNS) neurons
Guanosine diphosphate dissociation
Regulate the GDP-GTP exchange reaction of members of the Rab family,
small GTP-binding proteins of the Ras superfamily, that are involved in
vesicular trafficking of molecules between cellular organelles
Phosphoglycerate mutase (PGM)
Catalyzes the conversion of 3-phosphoglycerate (3PG) to 2-
phosphoglycerate (2PG) through a 2,3-bisphosphoglycerate intermediate
in glycolysis
Heat shock protein 70 (Hsp70)
Molecular chaperone and folding catalyst that assist in a variety of protein
folding processes in the cell by transient association of their substrate
binding domain with short hydrophobic peptide segments within their
substrate proteins
ATP synthase Provides energy for the cell to use through the synthesis of adenosinetriphosphate (ATP)
Alpha-spectrin Primary spectrin in blood that supports cell structure and critical for plateletactivation
Table 1. Nitrated proteins in TBI
Proteomics and the analysis of potential biomarkers for TBI have provided insight into the
mechanism and biochemistry of TBI, which have enabled opportunities to elucidate protein
behavior. The field of proteomics has assisted in yielding better insight to the progression of
injury, assessment of accurate diagnostic criteria for TBI, as well as the development of possible
therapies for TBI. The investigation and discovery of many candidate biomarkers for TBI will
continue to increase targeted proteomic experiments in the future.
13. Learning and memory
Traumatic brain injury (TBI) is a costly medical crisis for which no clinically proven pharma‐
cological therapies currently exist. TBI, also known as the “silent epidemic”, is profoundly
related to oxidative stress, which has been indicated as a mechanism of secondary neuronal
injury in TBI that can ultimately result in numerous related neurological maladies [155].
Oxidative stress has been associated in the pathogenesis of numerous neurological disorders
such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and stroke. TBIs could
impair coordination of respiratory muscles, pharyngeal function, and tongue/lip movement
involved with speech, which is one of the most complex functions humans can perform.
Incoordination of these precise processes can be detrimental and cause slurred or disjointed
speech. Problems can arise with expressive and receptive language, literacy abilities, and
diminished social communication skills. Furthermore, TBI in humans can cause an extensive
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range of cognitive impairments including, but are not limited to, a variety of deficits in
learning, memory, retrograde amnesia, anterograde amnesia, impairments in new learning or
acquisition, and deficits in working memory, reference memory, and spatial memory.
Impairments in memory are a core element of the cognitive deficits associated with TBI and
are likely related to disruption of cholinergic functioning in the hippocampus. Under oxidative
stress conditions, antioxidant levels fluctuate significantly. Certain environmental or external
factors may be the cause of an imbalance and as a result, reactive nitrogen species (RNS) are
created. RNS have the ability to react with biomolecules including carbohydrates, proteins,
lipids, DNA and RNA which leads to oxidative damage and ultimately cellular dysfunction
[156]. The brain is vulnerable to oxidative stress due to the high content of peroxidizable
unsaturated fatty acids, increased consumption of oxygen, elevated levels of free radicals, and
moderately low levels of antioxidant defense systems [157]. Damage to the brain from a
traumatic event can have life-long, lingering effects resulting in the deformation of normal
physiological processes. As a result of these biochemical events results, TBIs serve as a source
of significant and persistent cognitive dysfunction.
14. Conclusion
Traumatic brain injuries are a sudden, severe trauma to the brain. Presently, there is no cure
for these occurrences. These harmful injuries are the causative factors in a multitude of events
including protein dysfunction, altered energy metabolism, loss of enzymatic activity, and
increases in ROS and RNS. The field of proteomics has demonstrated the importance of how
oxidatively modified proteins play a pivotal role in both learning and memory, two key
features effected in traumatic brain injury. Current research efforts are introducing new animal
models and pre and post therapeutic strategies which show promise in delaying and possibly
preventing further neuronal damage for primary and secondary injuries associated with TBI,
making a clinical treatment for TBI a strong prospect in the near future.
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